Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 76 AL 90

Cross-disease protein aggregate interactions in neurodegeneration: from molecular mechanisms to therapeutic strategies

Yang W, Lu Y.

Neurol Sci. 2026 Sep 8;47(10):764. doi: 10.1007/s10072-026-09364-y.

Novel Therapeutic Insights Into Alzheimer's Disease: Glymphatic System and Meningeal Lymphatic Vessels

Song B, Wang W, Liu S, Jin X, Qi Y, Li M, Yue D, Liu Y, Li X, Yin L, Feng L.

Aging Cell. 2026 Sep;25(9):e70699. doi: 10.1111/acel.70699.

Quercetin-Based Nanotherapeutics for Targeted Drug Delivery in Alzheimer's Disease: Comparative Insights into Molecular Mechanisms, Blood-Brain Barrier Targeting and Therapeutic Perspectives

Begum MY, Rajkumar M, Govindaraj P, Velmani S, Rajkumar P, Sudha PN, Alhamod M, Alotaibi H.

Mol Neurobiol. 2026 Sep 16;63(1):900. doi: 10.1007/s12035-026-06188-x.

Targeting the BACE1-GSK-3β Signaling Axis in Alzheimer's Disease: From Molecular Crosstalk to Nanotechnology-Based Translational Strategies

Marimuthu A, Singh MT, Balasubramanian S, Krishnamurthy PT.

Mol Neurobiol. 2026 Sep 21;63(1):909. doi: 10.1007/s12035-026-06203-1.

Investigating the therapeutic potential of 1,2,3,4,6 penta-O-galloyl-β-D-glucose in Alzheimer's disease: a scoping review

Kahil E, Jackson A, D'Souza B, Gorman G, Jumbo-Lucioni P.

Nat Prod Res. 2026 Sep;40(17):5437-5451. doi: 10.1080/14786419.2025.2477226. Epub 2025 Mar 17.

Evaluating emerging amyloid-β centric drugs for the treatment of Alzheimer's disease

Lozupone M, Dibello V, Sardone R, Zupo R, Castellana F, Bortone I, Lampignano L, Di Matteo M, Moramarco G, Dellegrazie F, Daniele A, Solfrizzi V, Panza F.

Expert Opin Emerg Drugs. 2026 Sep;31(3):107-121. doi: 10.1080/14728214.2026.2693701. Epub 2026 Jun 30.

Apolipoprotein E in Alzheimer's disease: A review of APOE receptors, signalling pathways and therapeutic opportunities

Jayaram S, Easwaran V, Selvaraj D, Gunasekaran V, Soumya V, Thiruselvi M, Laxmana Prasanth M, Singh S, Ellaiyarasu C, Karthik Rai P, Gokula Priyan G, Thahideen A, Sabarieshwaran K.

Mol Cell Neurosci. 2026 Sep;138:104108. doi: 10.1016/j.mcn.2026.104108. Epub 2026 Jun 26.

Regulation of NLRP3 inflammasome signaling in Alzheimer's disease: emerging neuroprotective role of phytochemicals

Gupta A, Singh S, Singh TD.

Inflammopharmacology. 2026 Aug;34(8):5343-5363. doi: 10.1007/s10787-026-02324-0. Epub 2026 Jul 8.

Integration of multi-omics and artificial intelligence for therapeutic insights in Alzheimer's disease: A comprehensive review

Periyasamy TS, Sekar N, Lakshmanan H.

J Alzheimers Dis. 2026 Sep;113(2):519-542. doi: 10.1177/13872877261471812. Epub 2026 Jul 27.

HMGB1 signalling in Alzheimer's disease: pathogenic roles and therapeutic prospects

Tyagi P, Kumari S, Sharma P, Dhapola R, Paidlewar M, Medhi B, HariKrishnaReddy D.

Int Immunopharmacol. 2026 Oct 15;187:117204. doi: 10.1016/j.intimp.2026.117204. Epub 2026 Aug 6.

Brain organoids in Alzheimer disease and related tauopathies: Challenges and opportunities for translational readiness

Guruacharya A, Hartung T, Souza Dos Reis R, Moreira NCDS, Attisano L, Bolognin S, Iqbal K, Rajbanshi B.

Stem Cell Reports. 2026 Sep 8;21(9):103051. doi: 10.1016/j.stemcr.2026.103051. Epub 2026 Aug 20.

Icariside II in Neurological Disorders: Mechanistic Insights Into Alzheimer's Disease, Cerebral Ischemia and Parkinson's Disease

Solanki A, Sharma K, Jain J, Singh NK, Krishnamurthy PT.

J Biochem Mol Toxicol. 2026 Sep;40(9):e71093. doi: 10.1002/jbt.71093.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias